127 related articles for article (PubMed ID: 3610048)
21. A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therapy in chronic hepatitis B virus infection. A preliminary analysis of the first 32 patients.
Alexander GJ; Fagan EA; Guarner P; Rolando N; Brahm J; Eddleston AL; Williams R
J Hepatol; 1986; 3 Suppl 2():S183-8. PubMed ID: 3298406
[TBL] [Abstract][Full Text] [Related]
22. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
23. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
24. Occurrence of pre-S1 antigen in viremic and nonviremic carriers of hepatitis B surface antigen.
Budkowska A; Dubreuil P; Gerlich WH; Lazizi Y; Pillot J
J Med Virol; 1988 Oct; 26(2):217-25. PubMed ID: 2460586
[TBL] [Abstract][Full Text] [Related]
25. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
26. Serum HBsAg, HBeAg, anti-HBe, and hepatitis B viral DNA in asymptomatic carriers in Taiwan.
Chen DS; Lai MY; Lee SC; Yang PM; Sheu JC; Sung JL
J Med Virol; 1986 May; 19(1):87-94. PubMed ID: 3701304
[TBL] [Abstract][Full Text] [Related]
27. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).
Krogsgaard K; Bindslev N; Christensen E; Craxi A; Schlichting P; Schalm S; Carreno V; Trepo C; Gerken G; Thomas HC
J Hepatol; 1994 Oct; 21(4):646-55. PubMed ID: 7814812
[TBL] [Abstract][Full Text] [Related]
28. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.
Di Bisceglie AM; Fong TL; Fried MW; Swain MG; Baker B; Korenman J; Bergasa NV; Waggoner JG; Park Y; Hoofnagle JH
Am J Gastroenterol; 1993 Nov; 88(11):1887-92. PubMed ID: 8237937
[TBL] [Abstract][Full Text] [Related]
29. Activities of the interferon system in patients with HBsAg-positive chronic hepatitis B during short-term steroid withdrawal therapy.
Hirai N; Shimizu M; Morioka T; Hinoue Y; Tanaka N; Kobayashi K; Hattori N; Hashimoto T
Liver; 1988 Jun; 8(3):138-45. PubMed ID: 3393063
[TBL] [Abstract][Full Text] [Related]
30. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
31. The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment.
Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Li ZZ; Wu SL; Liu RY; Chang M; Hu LP; Hua WH; Song SJ; Wan G; Xie Y
Biomed Environ Sci; 2017 Mar; 30(3):177-184. PubMed ID: 28427487
[TBL] [Abstract][Full Text] [Related]
32. Interferon therapy of chronic hepatitis B virus infection in Chinese.
Lok AS; Lai CL; Wu PC
J Hepatol; 1986; 3 Suppl 2():S209-15. PubMed ID: 3036936
[TBL] [Abstract][Full Text] [Related]
33. Demonstration of a firm association between hepatitis B surface antigen proteins bearing polymerized human albumin binding sites and core-specific determinants in serum hepatitis B viral particles.
Petit MA; Capel F; Pillot J
Mol Immunol; 1985 Nov; 22(11):1279-87. PubMed ID: 2417111
[TBL] [Abstract][Full Text] [Related]
34. Enzyme-linked immunosorbent assay for detection of receptors for polymerized human serum albumin on hepatitis B surface antigen particles.
Tsuji T; Yamamoto I; Tsuchiya M; Nagashima H
J Immunol Methods; 1984 Oct; 73(2):357-66. PubMed ID: 6092478
[TBL] [Abstract][Full Text] [Related]
35. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
36. Expression of Pre-S-encoded proteins in sera of individuals chronically infected with hepatitis D virus.
Hess G; Möller B; Gerken G; Weber C; Manns M; Meyer zum Büschenfelde KH
Digestion; 1988; 40(1):61-4. PubMed ID: 3234618
[TBL] [Abstract][Full Text] [Related]
37. Treatment of chronic hepatitis B with human lymphoblastoid interferon: results of a controlled trial.
Mazzella G; Villanova N; Abdu-Ahmed M; Barbara L; Saracco G; Rizzetto M; Cancellieri C; Roda E
Chemioterapia; 1988 Dec; 7 Suppl 3():12-4. PubMed ID: 3073868
[TBL] [Abstract][Full Text] [Related]
38. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors.
Brook MG; Karayiannis P; Thomas HC
Hepatology; 1989 Nov; 10(5):761-3. PubMed ID: 2680866
[TBL] [Abstract][Full Text] [Related]
39. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy.
Saracco G; Mazzella G; Rosina F; Cancellieri C; Lattore V; Raise E; Rocca G; Giorda L; Verme G; Gasbarrini G
Hepatology; 1989 Sep; 10(3):336-41. PubMed ID: 2668148
[TBL] [Abstract][Full Text] [Related]
40. Lymphoblastoid alpha-interferon weekly, daily and combined with acyclovir for chronic HBeAg-positive hepatitis.
Schalm SW; Heytink RA; Van Buuren HR; De Man RA
J Hepatol; 1986; 3 Suppl 2():S189-92. PubMed ID: 3598156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
